This work aims to obtain an artificial neural network to simulate hospitalizations for respiratory diseases influenced by pollutant gaseous such as CO, PM, PM, NO, O, and SO emitted from 2011 to 2017, in the city of São Paulo. The hospitalization costs were also be calculated. MLP and RBF neural networks have been tested by varying the number of neurons in the hidden layer and the type of equation of the output function. The following pollutants and its concentration range were collected considering the supervision of Alto Tiete station set, in several neighborhoods in the city of São Paulo, from in the period 2011 to 2017: 28-63 µg/m of PM, 52-110 µg/m of PM, 49-135 µg/m of O, 0.8-2.6 ppm CO, 41-98 µg/m of NO, and 3-16 µg/m of SO. Results showed that a RBF neural network with 6 input neurons, 13 hidden layer neurons, and 1 output neuron, using BFGS algorithm and a Gaussian function to neuronal activation, was the best fitted to the experimental datasets. So, knowing the monthly concentration of gaseous pollutions was possible to predict the hospitalization of 1464 to 3483 ± 510 patients, with costs between 570,447 and 1,357,151 ± 198,171 USD per month. This way, it is possible to use this neural network to predict the costs of hospitalizing patients for respiratory diseases and to contribute to the decision-making of how much the government should spend on health care.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556003 | PMC |
http://dx.doi.org/10.1007/s11869-021-01077-9 | DOI Listing |
Alzheimers Dement
December 2024
Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
Background: The prohibitive costs of drug development for Alzheimer's Disease (AD) emphasize the need for alternative in silico drug repositioning strategies. Graph learning algorithms, capable of learning intrinsic features from complex network structures, can leverage existing databases of biological interactions to improve predictions in drug efficacy. We developed a novel machine learning framework, the PreSiBOGNN, that integrates muti-modal information to predict cognitive improvement at the subject level for precision medicine in AD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, DF, Mexico.
Background: The World Health Organization forecasts a population of 2,000 million people over 60 years by the year 2050, with 7% of this population suffering from dementia. Making a constant clinical-technological evaluation of older adults allows early detection of the disease and provides a better quality of life for the patient. In this sense, the research and development of innovative technological systems for the early detection of the disease, its monitoring and management of the growing number of patients with cognitive diseases has increased in recent years, integrating data collection and its automatic processing based on geriatric metrics into these systems using artificial intelligence (AI) methods.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: Dementia poses a significant global crisis, yet 60% of cases go undetected, particularly among specific sub-populations. Timely diagnosis is crucial for implementing early intervention strategies. Challenges of current screening tools (e.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
National University, Muscat, Muscat, Oman.
Background: This study explores Alzheimer's prediction through brain MRI images, utilizing Convolutional Neural Networks (CNNs) and Lime interpretability. Based on an extensive ADNI MRI dataset, we demonstrate promising results in predicting Alzheimer's disease. Local Interpretable Model Agnostic Explanations (LIME) shed light on decision-making processes, enhancing transparency.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Medical University of South Carolina, Charleston, SC, USA.
Background: Repetitive transcranial magnetic stimulation enhances cognition in people with mild cognitive impairment (MCI). Whereas conventional treatment requires daily sessions for 4-6 weeks, accelerated intermittent theta burst stimulation (iTBS) shortens the treatment course to just 3 days, substantially improving feasibility of use in people with MCI. We conducted a Phase I safety and feasibility trial of iTBS in MCI, finding preliminary evidence of cognitive improvement.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!